These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22172604)

  • 1. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
    Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
    Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
    Lee CK; Choi JS
    Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
    Choi BC; Choi JS; Han HK
    Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
    Li X; Choi JS
    Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges.
    Torne SJ; Ansari KA; Vavia PR; Trotta F; Cavalli R
    Drug Deliv; 2010 Aug; 17(6):419-25. PubMed ID: 20429848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
    Nornoo AO; Zheng H; Lopes LB; Johnson-Restrepo B; Kannan K; Reed R
    Eur J Pharm Biopharm; 2009 Feb; 71(2):310-7. PubMed ID: 18793723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
    Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
    Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
    Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
    Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats.
    Choi JS; Jo BW
    Int J Pharm; 2004 Aug; 280(1-2):221-7. PubMed ID: 15265561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cysteine on the pharmacokinetics of paclitaxel in rats.
    Lee YK; Han SY; Chin YW; Choi YH
    Arch Pharm Res; 2012 Mar; 35(3):509-16. PubMed ID: 22477198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
    Varma MV; Panchagnula R
    Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats.
    Choi JS; Shin SC
    Int J Pharm; 2005 Mar; 292(1-2):149-56. PubMed ID: 15725561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM; Beijnen JH; Rosing H; Koopman FJ; Jewell RC; Paul EM; Ten Bokkel Huinink WW; Schellens JH
    Br J Cancer; 2001 Jan; 84(1):42-7. PubMed ID: 11139311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin.
    Choi JS; Jo BW; Kim YC
    Eur J Pharm Biopharm; 2004 Mar; 57(2):313-8. PubMed ID: 15018990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.
    Yang LQ; Wang B; Gan H; Fu ST; Zhu XX; Wu ZN; Zhan DW; Gu RL; Dou GF; Meng ZY
    Biopharm Drug Dispos; 2012 Nov; 33(8):425-36. PubMed ID: 22898996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of verapamil on the pharmacokinetics of paclitaxel in rats.
    Choi JS; Li X
    Eur J Pharm Sci; 2005 Jan; 24(1):95-100. PubMed ID: 15626582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA; Alderden-Los C; Sharma A; Rosing H; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):43-50. PubMed ID: 16680462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.